The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Novel treatments for gastric cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the current field for novel gastric cancer treatments. The Phase III ATTRACTION-5 trial (NCT03006705) showed no statistical benefit of adding nivolumab to adjuvant chemotherapy in localized gastric cancer, post standard surgery. A press release indicated improved pathological complete response (pCR) with PD-L1 treatment combined with neoadjuvant chemotherapy, indicating as shift towards novel therapies or checkpoint inhibitors for gastric cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
